Cigarillo Public Education Messaging for Black Young Adults

ConditionCigarillo Smoking

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-30

SponsorDrexel University

About this trial

This is a 3-arm randomized controlled trial to examine the effects of cigarillo public education messages among Black young adults who are at-risk for established cigarillo smoking. The primary outcomes are cigarillo harm perceptions, outcome expectancies, and use intentions at 3-month follow-up. Exploratory outcomes are use behaviors (cigarillo smoking initiation and use behaviors) measured at 3-month follow-up. These outcomes will also be measured at 1-month follow-up time point.

Eligibility criteria

Qualifiers

Be between 18 to 30 years of age;

Self-identify as non-Hispanic Black or African American ethnicity and race, respectively;

Must be able to communicate, read, and write in the English language;

Have never used cigarillos fairly regularly based on a valid measure but are deemed susceptible to cigarillo smoking based on a valid 4-item susceptibility measure; OR currently smokes cigarillos some days but not every day (i.e., experimentation)

Disqualifiers

Persons who are younger than 18 years of age or older than 30 years of age.

Persons who do not self-identify as a non-Hispanic Black/African American person.

Persons who are not deemed susceptible based on a valid susceptibility measure (i.e., not susceptible to cigarillo smoking)

Persons who have fairly regular use of any tobacco product (i.e., persons with a former or current established pattern of any tobacco use including cigarillos, little cigars, large cigars, cigarettes, hookah tobacco, electronic vaping products, smokeless tobacco, and heated tobacco products)

Trial design

Treatments tested in this trial

Cigarillo Health Harm and Nicotine Addiction Messaging
Cigarillo Health Harm and Nicotine Addiction Messaging Contextualized to Outcome Expectancies

Treatment groups

360 Participants

are divided into 3 treatment groups

Sponsors and collaborators

Drexel University

Lead sponsor

National Cancer Institute (NCI)

Collaborator

Source ClinicalTrials.gov